Phase III clinical trial - Sein métastatique HER2+

DESTINY Breast 09
Sein métastatique HER2+
Ouvert depuis le: 03.02.2024
Site: Paris
Ouvert depuis le: 02.16.2022
Site: Saint-Cloud
Public cible
Adulte
Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
Description de l'essai
The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment.
JEAN-YVES PIERGA
Investigateur principal
Vignette
ETIENNE BRAIN
Investigateur principal